

DE by urine IL-6 Tertile
Tertile 1
Tertile 2
Tertile 3
DE
300
200
100
0
Kruskal-Wallis
ANOVA p=0.036

FIG. 1A



DE by plasma IL-6 Tertile
Tertile 1
Tertile 2
Tertile 3
DE
300
200
100
0
Kruskal-Wallis
ANOVA p=0.0018

FIG. 1B



DE by urine IL-6 Tertile (by rs855791)
Tertile 1
Tertile 2
Tertile 3
DE
300
200
100
0
AA
AG+GG
Kruskal-Wallis
ANOVA p=0.2134
Kruskal-Wallis
ANOVA p=0.0074

FIG. 2A



DE by plasma IL-6 Tertile (by rs855791)
Tertile 1
Tertile 2
Tertile 3
DE
300
200
100
0
AA
AG+GG
Kruskal-Wallis
ANOVA p=0.3895
Kruskal-Wallis
ANOVA p=0.0002

FIG. 2B



A
eGFR < 60 mL/min/1.73m2
Low Diuretic Efficiency
High Urine Angiotensinogen*
High Urine Renin*
High Plasma Renin*
Risk of Death**
0.1
1
10
OR or HR
for Urine IL-6, per SD increase
B
0.1
1
10
OR or HR
for Plasma IL-6, per SD increase

FIG. 3



NKCC2 expression
Fold increasement
4
3.5
3
2.5
2
1.5
1
0.5
0
control
IL6 10 ng/ml
IL6 100 ng/ml
IL6 500 ng/ml
Rux 1 uM
IL6 100 ng/ml+Rux 1 uM

FIG. 4A



ENaC-beta expression
Fold increasement
2.5
2
1.5
1
0.5
0
control
Il6 10 ng/ml
Il6 100 ng/ml
Il6 500 ng/ml
Rux 1 uM
Il6 100 ng/ml+Rux 1 uM

FIG. 4B



NCC expression
Fold increasement
2.5
2
1.5
1
0.5
0
control
IL6 10 ng/ml
IL6 100 ng/ml
IL6 500 ng/ml
Rux 100 uM
IL6 100 ng/ml+Rux 100 uM

FIG. 4C



NKCC2 expression
Fold increasement
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
control
IL6 10 ng/ml
IL6 100 ng/ml
IL6 500 ng/ml
Spir 100 uM
IL6 100 ng/ml+Spir 100 uM

FIG. 5A



ENaC-beta expression
Fold increasement
2.5
2
1.5
1
0.5
0
control
IL6 10 ng/ml
IL6 100 ng/ml
IL6 500 ng/ml
Spir 100 uM
IL6 100 ng/ml+Spir 100 uM

FIG. 5B



NCC expression
Fold increasement
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
control
IL6 10 ng/ml
IL6 100 ng/ml
IL6 500 ng/ml
Spir 1 uM
IL6 100 ng/ml+Spir 1 uM

FIG. 5C



BIOSTAT
NYHA IV
NYHA III
NYHA II
NYHA I
NTproBNP (log)
Atrial fibrillation
Anemia
Ischemic heart disease
SBP
egfr<60
Female sex
Age per 10 years
0.0
0.5
1.0
1.5
2.0
2.5
Odds ratio (95%CI)
Higher IL6

FIG. 6



All-cause mortality at 180 days
1st tertile
2nd tertile
3rd tertile
1.00
0.90
0.80
0.70
0.60
Log-rank test: P <0.001
0
50
100
150
200
Days

FIG. 7A



All-cause mortality or CV related rehospitalization at 60 days
1st tertile
2nd tertile
3rd tertile
1.00
0.90
0.80
0.70
0.60
0
20
40
60
Days
Log-rank test: P <0.001

FIG. 7B



All-cause mortality at 180 days
adjusted for IL-6
<1.0 pg/mL decrease or increase
>1.0 pg/mL decrease
>1.0 pg/mL increase
1.00
0.90
0.80
0
50
100
150
200
days

FIG. 8A



All-cause mortality or CV related rehospitalization at 60 days adjusted for IL-6
<1.0 pg/mL decrease or increase
>1.0 pg/mL decrease
>1.0 pg/mL increase
1.00
0.90
0.80
0
20
40
60
days

FIG. 8B



BIOSTAT
NYHA IV
NYHA III
NYHA II
NYHA I
NTproBNP (log)
Atrial fibrillation
Anemia
Ischemic heart disease
SBP
egfr<60
Female sex
Age per 10 years
0.0
0.5
1.0
1.5
2.0
2.5
Odds ratio (95%CI)
Higher IL6

FIG. 9



All-cause mortality and/or rehospitalization for HF at 2 years
1st tertile
2nd tertile
3rd tertile
1.00
0.90
0.80
0.70
0.60
0.50
0.40
P <0.001
0
.5
1
1.5
2
Years

FIG. 10A



All-cause mortality at 2 years
1st tertile
2nd tertile
3rd tertile
1.00
0.90
0.80
0.70
0.60
P <0.001
0
.5
1
1.5
2
Years

FIG. 10B



Patients with ferritin >100 ug/L
1st tertile
2nd tertile
3rd tertile
0.60
0.40
0.20
0.00
0
.5
1
1.5
2
analysis time
Log-rank: P <0.001

FIG. 11